A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Meng Zhao(Zhengzhou University), Bhuvaneswari Ramaswamy(The Ohio State University), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Macrae(McGill University), Charles L. Shapiro(Tisch Hospital), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Sarah Carothers(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maryam B. Lustberg(Yale Cancer Center), Xueliang Pan(The Ohio State University), Shannon Puhalla(UPMC Hillman Cancer Center), Robert Wesolowski(The Ohio State University Wexner Medical Center)
Cited by 17
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
|JAMA|2017|357
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296